Sandoz and Novartis recall prescription drug blister packages

Novartis and its Sandoz division have announced a recall involving blister packages of prescription drugs. According to the companies, the prescription drug packaging is not child-resistant, as required under the Poison Prevention Packaging Act.

Novartis and its Sandoz division have announced a recall involving blister packages of prescription drugs. According to the companies, the prescription drug packaging is not child-resistant, as required under the Poison Prevention Packaging Act. Approximately 470,000 units with 3&#8211;10 tablets per blister card are being recalled after the firms received a report of a child ingesting haloperidol from a blister pack. The recall affects drug packs from the two companies that were sold and clinics and pharmacies nationwide as a prescribed medicine from September 2016 to June 2018. The drugs were manufactured in Croatia, India, Ireland, Israel, Italy, Singapore, Spain, the United Kingdom, and the United States. Additional information about the recall, including the drugs and lot numbers affected, is available from the U.S. Consumer Product Safety Commission <a href="https://cpsc.gov/Recalls/2018/Sandoz-and-Novartis-Recall-Prescription-D…; target="_blank">here</a>.